309 related articles for article (PubMed ID: 12608887)
1. Benefits and risks of newer treatments for chemotherapy-induced and postoperative nausea and vomiting.
Kovac AL
Drug Saf; 2003; 26(4):227-59. PubMed ID: 12608887
[TBL] [Abstract][Full Text] [Related]
2. Granisetron. An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy.
Yarker YE; McTavish D
Drugs; 1994 Nov; 48(5):761-93. PubMed ID: 7530631
[TBL] [Abstract][Full Text] [Related]
3. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics.
Hsu ES
Am J Ther; 2010; 17(5):476-86. PubMed ID: 20844345
[TBL] [Abstract][Full Text] [Related]
4. A network meta-analysis on the efficacy of serotonin type 3 receptor antagonists used in adults during the first 24 hours for postoperative nausea and vomiting prophylaxis.
Tang DH; Malone DC
Clin Ther; 2012 Feb; 34(2):282-94. PubMed ID: 22296947
[TBL] [Abstract][Full Text] [Related]
5. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
Gregory RE; Ettinger DS
Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
[TBL] [Abstract][Full Text] [Related]
6. Prevention and treatment of postoperative nausea and vomiting.
Kovac AL
Drugs; 2000 Feb; 59(2):213-43. PubMed ID: 10730546
[TBL] [Abstract][Full Text] [Related]
7. Granisetron vs dolasetron for acute chemotherapy-induced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot study.
Tan M; Xu R; Seth R
Curr Med Res Opin; 2004 Jun; 20(6):879-82. PubMed ID: 15200746
[TBL] [Abstract][Full Text] [Related]
8. Is ondansetron more effective than granisetron for chemotherapy-induced nausea and vomiting? A review of comparative trials.
Vrabel M
Clin J Oncol Nurs; 2007 Dec; 11(6):809-13. PubMed ID: 18063539
[TBL] [Abstract][Full Text] [Related]
9. Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting.
Markham A; Sorkin EM
Drugs; 1993 Jun; 45(6):931-952. PubMed ID: 7691500
[TBL] [Abstract][Full Text] [Related]
10. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
11. Ondansetron: a serotonin receptor (5-HT3) antagonist for antineoplastic chemotherapy-induced nausea and vomiting.
Kohler DR; Goldspiel BR
DICP; 1991 Apr; 25(4):367-80. PubMed ID: 1833888
[TBL] [Abstract][Full Text] [Related]
12. Spectrum of use and tolerability of 5-HT3 receptor antagonists.
Haus U; Späth M; Färber L
Scand J Rheumatol Suppl; 2004; 119():12-8. PubMed ID: 15515406
[TBL] [Abstract][Full Text] [Related]
13. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy?
Schwartzberg LS
Oncology (Williston Park); 2007 Jul; 21(8):946-53; discussion 954, 959, 962 passim. PubMed ID: 17715696
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
16. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting.
Perez EA
Cancer J Sci Am; 1998; 4(2):72-7. PubMed ID: 9532406
[TBL] [Abstract][Full Text] [Related]
17. Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting.
Plosker GL; Benfield P
Pharmacoeconomics; 1996 Apr; 9(4):357-74. PubMed ID: 10160110
[TBL] [Abstract][Full Text] [Related]
18. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
Sorbe BG
Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of ramosetron for preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis.
Song HJ; Seo HJ; Son H
Eur J Clin Pharmacol; 2016 Nov; 72(11):1289-1301. PubMed ID: 27526189
[TBL] [Abstract][Full Text] [Related]
20. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]